Editorial
doi: 10.1007/s10620-022-07661-y.
Epub 2022 Sep 13.
Secondary Treatment of Primary Biliary Cholangitis: Early Prediction of Inadequate Response to Ursodeoxycholic Acid in Patients with PBC
Affiliations
- PMID: 36098875
- DOI: 10.1007/s10620-022-07661-y
Item in Clipboard
Editorial
Secondary Treatment of Primary Biliary Cholangitis: Early Prediction of Inadequate Response to Ursodeoxycholic Acid in Patients with PBC
Dig Dis Sci.
2023 Feb.
No abstract available
Comment on
-
Response to Ursodeoxycholic Acid May Be Assessed Earlier to Allow Second-Line Therapy in Patients with Unresponsive Primary Biliary Cholangitis.Dig Dis Sci. 2023 Feb;68(2):514-520. doi: 10.1007/s10620-022-07654-x. Epub 2022 Aug 22. Dig Dis Sci. 2023. PMID: 35989386
Similar articles
-
[Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].Zhonghua Gan Zang Bing Za Zhi. 2019 Jan 20;27(1):73-76. doi: 10.3760/cma.j.issn.1007-3418.2019.01.018. Zhonghua Gan Zang Bing Za Zhi. 2019. PMID: 30685931 Chinese.
-
Seladelpar in patients with primary biliary cholangitis: Need for a closer look!J Hepatol. 2022 Nov;77(5):1451. doi: 10.1016/j.jhep.2022.04.039. Epub 2022 May 17. J Hepatol. 2022. PMID: 35594993 No abstract available.
-
Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit.Gut. 2020 Aug;69(8):1377-1378. doi: 10.1136/gutjnl-2019-320355. Epub 2020 Mar 23. Gut. 2020. PMID: 32205421 No abstract available.
-
Treatment of Primary Biliary Cholangitis: First-Line and Second-Line Therapies.Clin Liver Dis. 2022 Nov;26(4):705-726. doi: 10.1016/j.cld.2022.06.012. Epub 2022 Sep 14. Clin Liver Dis. 2022. PMID: 36270725 Review.
-
Toward precision medicine in primary biliary cholangitis.Dig Liver Dis. 2016 Aug;48(8):843-50. doi: 10.1016/j.dld.2016.05.023. Epub 2016 Jun 3. Dig Liver Dis. 2016. PMID: 27324985 Review.
Cited by
-
Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases.Front Med (Lausanne). 2025 Feb 6;12:1494248. doi: 10.3389/fmed.2025.1494248. eCollection 2025. Front Med (Lausanne). 2025. PMID: 39981079 Free PMC article.
References
-
- Kim WR, Lindor KD, Locke GR 3rd, Therneau TM, Homburger HA, Batts KP et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology. 2000;119:1631–1636. - DOI
-
- Arndtz K, Hirschfield GM. The pathogenesis of autoimmune liver disease. Dig Dis (Basel, Switzerland). 2016;34:327–333. - DOI
-
- Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med. 1983;308:1–7. - DOI
-
- Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology (Baltimore, Md). 1989;10:1–7. - DOI
-
- Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;12(12):CD000551-CD.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
